全文获取类型
收费全文 | 5639篇 |
免费 | 529篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 68篇 |
儿科学 | 157篇 |
妇产科学 | 96篇 |
基础医学 | 757篇 |
口腔科学 | 92篇 |
临床医学 | 717篇 |
内科学 | 1121篇 |
皮肤病学 | 27篇 |
神经病学 | 642篇 |
特种医学 | 158篇 |
外科学 | 965篇 |
综合类 | 35篇 |
一般理论 | 3篇 |
预防医学 | 381篇 |
眼科学 | 176篇 |
药学 | 493篇 |
1篇 | |
中国医学 | 3篇 |
肿瘤学 | 282篇 |
出版年
2021年 | 98篇 |
2020年 | 49篇 |
2019年 | 85篇 |
2018年 | 82篇 |
2017年 | 81篇 |
2016年 | 75篇 |
2015年 | 68篇 |
2014年 | 123篇 |
2013年 | 166篇 |
2012年 | 252篇 |
2011年 | 255篇 |
2010年 | 128篇 |
2009年 | 151篇 |
2008年 | 222篇 |
2007年 | 212篇 |
2006年 | 246篇 |
2005年 | 238篇 |
2004年 | 189篇 |
2003年 | 178篇 |
2002年 | 162篇 |
2001年 | 159篇 |
2000年 | 182篇 |
1999年 | 128篇 |
1998年 | 46篇 |
1994年 | 43篇 |
1993年 | 47篇 |
1992年 | 162篇 |
1991年 | 134篇 |
1990年 | 160篇 |
1989年 | 137篇 |
1988年 | 134篇 |
1987年 | 136篇 |
1986年 | 129篇 |
1985年 | 124篇 |
1984年 | 101篇 |
1983年 | 87篇 |
1982年 | 59篇 |
1981年 | 55篇 |
1980年 | 53篇 |
1979年 | 87篇 |
1978年 | 84篇 |
1977年 | 80篇 |
1976年 | 62篇 |
1975年 | 53篇 |
1974年 | 82篇 |
1973年 | 79篇 |
1972年 | 48篇 |
1971年 | 48篇 |
1970年 | 55篇 |
1969年 | 43篇 |
排序方式: 共有6174条查询结果,搜索用时 14 毫秒
1.
Bergman David Modh Ankit Schultz Lonni Snyder James Mikkelsen Tom Shah Mira Ryu Samuel Siddiqui M. Salim Walbert Tobias 《Journal of neuro-oncology》2020,148(2):353-361
Journal of Neuro-Oncology - Outcomes for patients with recurrent high-grade glioma (HGG) progressing on bevacizumab (BEV) are dismal. Fractionated stereotactic radiosurgery (FSRS) has been shown to... 相似文献
2.
Daniel J. Snyder Thomas R. Kroshus Aakash Keswani Evan B. Garden Karl M. Koenig Kevin J. Bozic David S. Jevsevar Jashvant Poeran Calin S. Moucha 《The Journal of arthroplasty》2019,34(4):613-618
Background
Nursing Home Compare (NHC) ratings, created and maintained by Medicare, are used by both hospitals and consumers to aid in the skilled nursing facility (SNF) selection process. To date, no studies have linked NHC ratings to actual episode-based outcomes. The purpose of this study was to evaluate whether NHC ratings are valid predictors of 90-day complications, readmission, and bundle costs for patients discharged to an SNF after primary total joint arthroplasty (TJA).Methods
All SNF-discharged primary TJA cases in 2017 at a multihospital academic health system were queried. Demographic, psychosocial, and clinical variables were manually extracted from the health record. Medicare NHC ratings were then collected for each SNF. For patients in the Medicare bundle, postacute and total bundle cost was extracted from claims.Results
Four hundred eighty-eight patients were discharged to a total of 105 unique SNFs. In multivariate analysis, overall NHC rating was not predictive of 90-day readmission/major complications, >75th percentile postacute cost, or 90-day bundle cost exceeding the target price. SNF health inspection and quality measure ratings were also not predictive of 90-day readmission/major complications or bundle performance. A higher SNF staffing rating was independently associated with a decreased odds for >75th percentile 90-day postacute spend (odds ratio, 0.58; P = .01) and a 90-day bundle cost exceeding the target price (odds ratio = 0.69; P = .02) but was similarly not predictive of 90-day readmission/complications.Conclusion
Results of our study suggest that Medicare's NHC tool is not a useful predictor of 90-day costs, complications, or readmissions for SNFs within our health system. 相似文献3.
John G. Baust Kristi K. Snyder Kimberly L. Santucci Anthony T. Robilotto Robert G. Van Buskirk John M. Baust 《International journal of hyperthermia》2019,36(2):10-16
AbstractCryoablation (CA) is unique as the singular energy deprivation therapy that impacts all cellular processes. CA is independent of cell cycle stage and degree of cellular stemness. Importantly, CA is typically applied as a non-repetitive (single session) treatment that does not support adaptative mutagenesis as do many repetitive therapies. CA is characterized by the launch of multiple forms of cell death including (a) ice-related physical damage, (b) initiation of cellular stress responses (kill switch activation) and launch of necrosis and apoptosis, (c) vascular stasis, and (d) likely activation of ablative immune responses. CA is not without limitation related to the thermal gradient formed between cryoprobe surface (~?185°C) and the distal surface of the freeze zone (~0°C) requiring freeze margin extension beyond the tumor boundary (up to ~1?cm). This limitation is mitigated in part by commonly applied dual freeze thaw cycles and the use of freeze sensitizing adjuvants. This review will (1) identify the cascade of damaging effects of the freeze–thaw process, its physical and molecular-based relationships, (2) a likely immunological involvement (abscopic effect), and (3) explore the use of freeze-sensitizing adjuvants necessary to limit freezing beyond the tumor margin. 相似文献
4.
Alexander D. Sherry MD Kelsey L. Corrigan MD MPH Ramez Kouzy MD Joseph Abi Jaoude MD Yumeng Yang MS Roshal R. Patel MD Douglas J. Totten MD MBA Neil B. Newman MD MS Prajnan Das MD MS MPH Cullen Taniguchi MD PhD Bruce Minsky MD Rebecca A. Snyder MD MPH C. David Fuller MD PhD Ethan Ludmir MD 《Cancer》2023,129(21):3430-3438
5.
Vickie R. Driver Kara S. Couch Kristen A. Eckert Gary Gibbons Lorena Henderson John Lantis Eric Lullove Paul Michael Richard F. Neville Lee C. Ruotsi Robert J. Snyder Fadi Saab Marissa J. Carter 《Wound repair and regeneration》2022,30(1):7-23
In the wake of the coronavirus pandemic, the critical limb ischemia (CLI) Global Society aims to develop improved clinical guidance that will inform better care standards to reduce tissue loss and amputations during and following the new SARS-CoV-2 era. This will include developing standards of practice, improve gaps in care, and design improved research protocols to study new chronic limb-threatening ischemia treatment and diagnostic options. Following a round table discussion that identified hypotheses and suppositions the wound care community had during the SARS-CoV-2 pandemic, the CLI Global Society undertook a critical review of literature using PubMed to confirm or rebut these hypotheses, identify knowledge gaps, and analyse the findings in terms of what in wound care has changed due to the pandemic and what wound care providers need to do differently as a result of these changes. Evidence was graded using the Oxford Centre for Evidence-Based Medicine scheme. The majority of hypotheses and related suppositions were confirmed, but there is noticeable heterogeneity, so the experiences reported herein are not universal for wound care providers and centres. Moreover, the effects of the dynamic pandemic vary over time in geographic areas. Wound care will unlikely return to prepandemic practices. Importantly, Levels 2–5 evidence reveals a paradigm shift in wound care towards a hybrid telemedicine and home healthcare model to keep patients at home to minimize the number of in-person visits at clinics and hospitalizations, with the exception of severe cases such as chronic limb-threatening ischemia. The use of telemedicine and home care will likely continue and improve in the postpandemic era. 相似文献
6.
David G. Armstrong Dennis P. Orgill Robert Galiano Paul M. Glat Lawrence Didomenico Alexander Reyzelman Robert Snyder William W. Li Marissa Carter Charles M. Zelen 《International wound journal》2022,19(1):64-75
We desired to carefully evaluate a novel autologous heterogeneous skin construct in a prospective randomised clinical trial comparing this to a standard-of-care treatment in diabetic foot ulcers (DFUs). This study reports the interim analysis after the first half of the subjects have been analysed. Fifty patients (25 per group) with Wagner 1 ulcers were enrolled at 13 wound centres in the United States. Twenty-three subjects underwent the autologous heterogeneous skin construct harvest and application procedure once; two subjects required two applications due to loss of the first application. The primary endpoint was the proportion of wounds closed at 12 weeks. There were significantly more wounds closed in the treatment group (18/25; 72%) vs controls (8/25; 32%) at 12 weeks. The treatment group achieved significantly greater percent area reduction compared to the control group at every prespecified timepoint of 4, 6, 8, and 12 weeks. Thirty-eight adverse events occurred in 11 subjects (44%) in the treatment group vs 48 in 14 controls (56%), 6 of which required study removal. In the treatment group, there were no serious adverse events related to the index ulcer. Two adverse events (index ulcer cellulitis and bleeding) were possibly related to the autologous heterogeneous skin construct. Data from this planned interim analysis support that application of autologous heterogeneous skin construct may be potentially effective therapy for DFUs and provide supportive data to complete the planned study. 相似文献
7.
J. M. Smith T. Weaver M. A. Skeans S. P. Horslen E. Miller S. M. Noreen J. J. Snyder A. K. Israni B. L. Kasiske 《American journal of transplantation》2020,20(Z1):300-339
Despite medical and surgical advances in treatment of intestinal failure, intestine transplant still plays an important role. However, the number of new patients added to the intestine transplant waiting list has decreased over the past decade, reaching a low of 135 in 2018. The number of intestine donors also decreased, reaching a low of 106 in 2018, and the number of intestine transplants performed declined to its lowest level, 104, of which 59% were intestine‐liver transplants. Graft failure has plateaued over the past decade. Patient survival for transplants in 2011‐2013 varied by age and transplant type. Patient survival was lowest for adult intestine‐liver recipients (1‐and 5‐year survival 66.7% and 49.1%, respectively) and highest for pediatric intestine recipients (1‐and 5‐year survival 89.1% and 76.4%, respectively). 相似文献
8.
R. Kandaswamy P. G. Stock S. K. Gustafson M. A. Skeans R. Urban A. Fox A. K. Israni J. J. Snyder B. L. Kasiske 《American journal of transplantation》2020,20(Z1):131-192
The overall number of pancreas transplants continued to increase to 1027 in 2018, after a nadir of 947 in 2015. New additions to waiting list remained stable, with 1485 candidates added in 2018. Proportions of patients with type II diabetes waiting for transplant (14.6%) and undergoing transplant (14.8%) have steadily increased since 2016. Waiting times for simultaneous pancreas/kidney transplant have decreased; median months to transplant was 13.5 for simultaneous pancreas/kidney transplant and 19.7 for pancreas transplant alone in 2018. Outcomes, including patient and kidney survival, as well as rejection rates, have improved consistently over the past several years. Pancreas graft survival data are being collected by the Organ Procurement and Transplantation Network and will be included in a future report once there are sufficient cohorts for analysis. 相似文献
9.
10.
Monzr M. Al Malki Nitya Nathwani Dongyun Yang Saro Armenian Sanjeet Dadwal Jaroslava Salman Sally Mokhtari Thai Cao Karamjeet Sandhu Michelle Rouse Matthew Mei Haris Ali Pablo Parker Joseph Alvarnas Eileen Smith Margaret O. Donnell Guido Marcucci David Snyder Ryotaro Nakamura 《Biology of blood and marrow transplantation》2018,24(9):1828-1835
Allogeneic hematopoietic stem cell transplantation (alloHCT) is offered increasingly to elderly patients with hematologic malignancies. However, outcome data in those who are 70 years or older are limited, and no standard conditioning regimen has been established for this population. In this retrospective study we evaluated the outcome of 53 consecutive patients aged 70 years and older who underwent alloHCT with melphalan-based reduced-intensity conditioning (RIC) at City of Hope. Engraftment was prompt, with median time to neutrophil engraftment of 15 days. More than 95% of patients achieved complete donor chimerism within 6 weeks from HCT, consistent with the “semiablative” nature of this regimen. With a median follow-up of 31.1 months, the 2-year overall survival (OS), progression-free survival (PFS), and nonrelapse mortality (NRM) were 68.9%, 63.8%, and 17.0%, respectively. Cumulative incidence of relapse at 1 and 2 years was 17.0% and 19.3%, respectively. One hundred–day cumulative incidence of grades II to IV acute graft-versus-host disease was 37.7% (grades III to IV, 18.9%), and 2-year cumulative incidence of chronic graft-versus-host disease was 61.9% (extensive, 45.9%). The only significant predictor for poor OS was high/very high disease risk index. Transplant-related complications and morbidities observed here did not differ from the commonly expected in younger patients treated with RIC. In conclusion, alloHCT with a melphalan-based conditioning regimen is associated with acceptable toxicities and NRM, lower incidence of relapse, and favorable OS and PFS in patients aged 70 years or older. 相似文献